What the gene therapy pipeline means for autism

The first child received JAG201, a gene therapy for Phelan-McDermid syndrome, in February 2025. A 24 February 2026 BusinessWire release reported that Cohort 1 dosing was complete — that announcement was not the first dose.

That timeline needs some unpacking — because what it means, and what it does not mean, are both important.

The three approaches currently in or near humans

JAG201 — Phelan-McDermid Syndrome

Phelan-McDermid Syndrome is caused by deletions or mutations in the SHANK3 gene on chromosome 22. SHANK3 codes for a protein that is critical for the connections between nerve cells. When one copy is missing or damaged, those connections do not form properly.

JAG201 is a one-time AAV9 gene therapy that delivers a working SHANK3 minigene into the brain (intracerebroventricular injection). It is in a Phase 1/2 first-in-human trial (ClinicalTrials.gov NCT06662188) for people with confirmed SHANK3 haploinsufficiency / Phelan-McDermid syndrome — not for autism without that genetic finding.

Sites so far include the Seaver Autism Center at Mount Sinai (New York), Rush University (Chicago), and Boston Children’s Hospital. Paediatric cohorts (ages 2–9) enrol first; adult cohorts may open later.

Public updates are still company-reported, not peer-reviewed outcomes. Jaguar said Cohort 1 dosing was complete in February 2026. A July 2026 community update reported seven paediatric patients dosed across those sites, with no treatment-related serious adverse events claimed so far and early signals across communication, motor, cognitive, and social domains. Treat those signals as preliminary.

For UK families: a genetic diagnosis of SHANK3-related Phelan-McDermid can change what research pathways exist. It does not mean gene therapy is available on the NHS, and it does not apply to most autistic children.

CRISPRa — SCN2A and CHD8

This approach is different in a subtle but important way. Standard CRISPR editing cuts DNA. CRISPRa does not cut anything. Instead, it attaches to the promoter region of a gene and turns up its activity — like increasing the volume on the working copy of a gene that is present but underexpressed.

This matters enormously in autism genetics, because many high-confidence autism genes are haploinsufficient. You have two copies. One is faulty. The other is functional but not working hard enough on its own. CRISPRa nudges the healthy copy to compensate.

This approach has now been demonstrated in neurons and in brain organoids — lab-grown tissue that mimics brain development — for two of the most frequently mutated genes in autism: SCN2A and CHD8. The SCN2A approach has been licensed to Regel Therapeutics for clinical development. CHD8 is among the most frequently reported loss-of-function autism genes, not the most commonly mutated single gene, and it is now a target.

Zorevunersen — Dravet Syndrome

Dravet Syndrome is caused by loss-of-function mutations in SCN1A, a gene that codes for a sodium channel critical to inhibitory neurons in the brain. It produces a severe, treatment-resistant epilepsy that begins in infancy, and it carries significant cognitive and developmental consequences.

Zorevunersen is an antisense oligonucleotide — a short piece of synthetic genetic material that modulates how the remaining functional copy of SCN1A is read. In open-label phase 1–2a data published in the New England Journal of Medicine (Laux et al.), children who received the high-dose (70 mg) regimen had a median reduction in convulsive-seizure frequency ranging up to about 91% across 1-month intervals in the extension studies. That figure is the top of an open-label high-dose range, not an RCT effect. Phase 3 trials are now enrolling in the UK, the United States, and Japan.

Dravet Syndrome is not an autism diagnosis, but it illustrates the same genetic principle at work across this pipeline: haploinsufficiency correction. Fix the gene dose. Reduce the downstream harm.

What this is not

None of these approaches are about changing autistic people. None of them are about erasing autism. None of them are targeted at the social and communication profile that defines autism as a neurodevelopmental condition.

They are targeted at the medical complications that arise in specific genetic subtypes — severe seizures, profound intellectual disability, loss of spoken language. These are the consequences that cause the greatest suffering and the greatest reduction in quality of life, for the person and for their family.

The distinction matters. Autism is not a disease to be eliminated. But within the autism spectrum there are children whose seizures are catastrophic, whose language never develops, whose cognitive impairment is severe — and for them, a gene-specific intervention that addresses the biological mechanism causing that harm is not a threat to neurodiversity. It is treatment.

A pattern worth understanding

What connects JAG201, CRISPRa, and Zorevunersen is a shared logic: identify the gene, understand the mechanism, correct the dose.

This is precision medicine arriving at autism. Not for all autism — that would be a category error, because autism is not one condition caused by one gene. But for the subset of autism where a single high-confidence gene is the primary driver, the pipeline is real, it is moving, and some of it is already in humans.

For families who have received a genetic diagnosis — SHANK3, SCN2A, CHD8, SCN1A, or any of the growing list of high-confidence autism genes — it is worth staying close to this literature. The landscape is changing quickly.

For everyone else, the most useful thing to understand is the distinction between treating the medical complications of a genetic condition and changing what it means to be autistic. Both conversations need to happen. They should not be confused with each other.

References

1. ClinicalTrials.gov. A Study of JAG201 in Participants With SHANK3 Haploinsufficiency / Phelan-McDermid Syndrome. Identifier: NCT06662188.
2. Mount Sinai / Seaver Autism Center. JAG201 clinical trial information for Phelan-McDermid syndrome. mountsinai.org (trial site page; confirm current listing).
3. Jaguar Gene Therapy. Successful completion of dosing of first patient cohort in clinical trial evaluating JAG201 for the treatment of Phelan-McDermid Syndrome. BusinessWire, 24 February 2026. Company-reported preliminary data; not peer-reviewed outcomes.
4. Jaguar Gene Therapy / Phelan-McDermid syndrome community update, July 2026 (company/community communication; treat as preliminary).
5. The Transmitter — CRISPRa for SCN2A and CHD8.
6. Laux L, Sullivan J, Perry MS, Brunklaus A, Desurkar A, Schreiber JM, Roberts CM, Knupp KG, Wheless JW, Wirrell EC, Ventola P, Wang F, Meena, Lynch J, Parkerson KA, Ticho B, Cross JH. Zorevunersen in children and adolescents with Dravet syndrome. New England Journal of Medicine. 2026;394(10):969–982. https://doi.org/10.1056/nejmoa2506295

---

Dr Odet Aszkenasy is a Consultant Community Paediatrician and the author of The Genetics of Autism: A Guide for Parents and Professionals.